Stay updated with breaking news from Sun Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The scarcity of several medications in the US presents Indian pharma players with a great chance to expand market share, regulatory hurdles and industry dynamics allowing.
It says Ebitda margins may reach 24.9%, boosted by product mix and cost control; long-term growth outlook positive, focused on complex products, domestic demand, and R&D investments
The conflict in the Middle East could impact Indian pharma exports to the MENA region, potentially leading to supply chain disruptions and shortages of essential drugs. Key Indian pharma companies like Sun Pharma, Dr Reddy's, and Lupin may be affected.
In sectoral trends on NSE, Nifty Healthcare, Nifty Pharma, Nifty Banks and Nifty Fin Services led losses
Among broader markets and sectors, the banking gauge, the Nifty Bank slipped 474 points to 48,564. The midcap index also declined by 313 points, closing at 50,068.